SCHEMBL7745172

SCHEMBL7745172

CC(C)(C)NCCN1CCNC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.48
RAB9A P51151 1/20 0.48
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 3/20 0.43
LMNA P02545 1/20 0.43
CREBBP Q92793 1/20 0.39
MEN1 O00255 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 3/20 0.38
RET P07949 1/20 0.38
KDR P35968 1/20 0.38
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
HPGDS O60760 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284635 0.80 KMT2A (0.49) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL6284446 0.79 KMT2A (0.51) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL471729 0.79 ALDH1A1 (0.50) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL6107954 0.77 KDM4E (0.42) KMT2AALDH1A1KDM4ELMNAPOLB
SCHEMBL22030392 0.77 ALDH1A1 (0.49) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL11419796 0.77 KMT2A (0.49) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL15964104 0.77 KMT2A (0.57) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL13236669 0.76 ALDH1A1 (0.50) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL16588388 0.76 KMT2A (0.48) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL7767345 0.76 KMT2A (0.41) KMT2ARAB9AALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200269187-A1 ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE EXXONMOBIL RESEARCH AND ENGINEERING COMPANY 2020-08-27 US claimed
EP-3678756-A1 ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE BASF SE (DE) 2020-07-15 EP claimed
CN-111093803-A Absorbent and process for selective removal of hydrogen sulfide 巴斯夫欧洲公司 2020-05-01 CN claimed
WO-2019043099-A1 ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE BASF SE (DE) 2019-03-07 WO claimed
US-11458433-B2 Absorbent and process for selectively removing hydrogen sulfide BASF SE (DE) 2022-10-04 US disclosed
CN-111093803-B Absorbent and process for selective removal of hydrogen sulfide 巴斯夫欧洲公司 2022-06-24 CN disclosed
EP-3678756-B1 ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE BASF SE (DE) 2021-06-30 EP disclosed
US-20200269187-A1 ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE EXXONMOBIL RESEARCH AND ENGINEERING COMPANY 2020-08-27 US disclosed
EP-3678756-A1 ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE BASF SE (DE) 2020-07-15 EP disclosed
CN-111093803-A Absorbent and process for selective removal of hydrogen sulfide 巴斯夫欧洲公司 2020-05-01 CN disclosed
WO-2019043099-A1 ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE BASF SE (DE) 2019-03-07 WO disclosed
US-9580415-B2 Compounds PROXIMAGEN LIMITED (GB) 2017-02-28 US disclosed
US-20090192177-A1 2-ARYL pyrrologpyrimidines for A1 and A3 receptors OSI PHARMACEUTICALS, INC. 2009-07-30 US disclosed
US-20090082369-A1 Pyrrolo[2,3d]pyrimidine compositions and their use OSI PHARMACEUTICALS, INC. 2009-03-26 US disclosed
US-7504407-B2 Compounds specific to adenosine A1 and A3 receptors and uses thereof OSI PHARMACEUTICALS, INC. (US) 2009-03-17 US disclosed
US-7429574-B2 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use OSI PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed
US-20080070936-A1 Compounds specific to adenosine A1 receptors and uses thereof OSI PHARMACEUTICALS, INC. 2008-03-20 US disclosed
US-20080070936-A1 Compounds specific to adenosine A1 receptors and uses thereof OSI PHARMACEUTICALS, INC. 2008-03-20 US disclosed
US-7160890-B2 Compounds specific to adenosine A3 receptor and uses thereof OSI PHARMACEUTICALS, INC. (US) 2007-01-09 US disclosed
US-6680324-B2 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2004-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192177-A1 2-ARYL pyrrologpyrimidines for A1 and A3 receptors ADORA3, ADORA1, ADORA2A KMT2A 2686/4885RAB9A 2270/4885ALDH1A1 265/4885
US-20090082369-A1 Pyrrolo[2,3d]pyrimidine compositions and their use ADORA3, ADORA2A, ADORA1 KMT2A 1854/4885RAB9A 1426/4885ALDH1A1 1671/4885
US-20080070936-A1 Compounds specific to adenosine A1 receptors and uses thereof ADORA1, ADORA2A, ADORA3 KMT2A 2532/4885RAB9A 1884/4885ALDH1A1 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.